Welcome to our dedicated page for Veru news (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru stock.
Veru Inc. develops late clinical-stage biopharmaceutical programs for cardiometabolic and inflammatory diseases. Company news centers on clinical development of enobosarm, an oral selective androgen receptor modulator being studied with GLP-1 receptor agonist therapy to make weight reduction more selective for fat loss while preserving lean mass, physical function, and bone.
Recurring updates also cover sabizabulin, an oral microtubule disruptor being developed for chronic inflammation related to atherosclerotic cardiovascular disease. Veru’s announcements commonly include fiscal results, business updates, clinical-study progress, regulatory feedback, scientific presentations, and conference webcasts tied to its small-molecule pipeline.
Veru Inc. (NASDAQ: VERU) has received FDA Fast Track designation for enobosarm, aimed at treating AR+ ER+ HER2- metastatic breast cancer. This designation is significant for expediting drug development for serious conditions. Enobosarm is currently being evaluated in the Phase 3 ARTEST study for patients who have progressed on multiple therapies. The company is dedicated to developing innovative treatments for breast and prostate cancers, with ongoing studies to improve patient outcomes in challenging cases.
Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company, will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022, starting at 7:00 am EST on January 10th. A webcast of the presentation will be available on their website, which will remain accessible for 30 days. Veru focuses on developing treatments for breast and prostate cancers, including enobosarm and sabizabulin. The company also has a sexual health division, funding its drug development. Current studies include late-stage trials for these cancer treatments and a Phase 3 COVID-19 study for sabizabulin.
Veru Inc. (NASDAQ: VERU) announced the FDA approval of ENTADFI (finasteride and tadalafil) for treating benign prostatic hyperplasia (BPH), addressing urinary tract symptoms in men. This capsule, taken once daily, is more effective than finasteride alone with fewer sexual side effects. Commercialization is set for early 2022 through Veru’s telemedicine and partnerships with GoodRx, aiming to tap into the multi-billion dollar BPH market. The approval represents a key milestone for Veru, boosting potential revenue streams to fund further oncology research.
Veru Inc. (NASDAQ: VERU) announced promising human preclinical data for its drug enobosarm, which shows enhanced androgen receptor expression and tumor suppression when used alone or with the CDK4/6 inhibitor palbociclib. Presented at the San Antonio Breast Cancer Symposium, the findings suggest that this combination may effectively combat resistant breast cancer types. Veru's ongoing Phase 3 trials for enobosarm, aimed at AR+ER+HER2- metastatic breast cancer patients, are supported by these results, which highlight enobosarm's potential as a targeted therapy.
Veru Inc. (NASDAQ: VERU) reported a 44% increase in fiscal 2021 net revenues, reaching $61 million, and a 56% rise in gross profit to $48 million. The fourth quarter saw net revenues climb 33% to $15.6 million and gross profit rise 29% to $12.3 million. Operating loss improved to $1.9 million from $11.3 million in FY2020. The company is advancing multiple clinical programs, including Phase 3 studies for sabizabulin, targeting COVID-19 and metastatic cancers. Anticipated clinical results for COVID-19 are expected in 1H 2022.
Veru Inc. (NASDAQ: VERU) will report its fiscal 2021 fourth quarter and full-year financial results on December 2, 2021, before market opens. Management will conduct a conference call at 8 a.m. ET to discuss the performance and answer questions. Veru focuses on oncology, developing treatments for breast and prostate cancer, including ongoing studies for drugs like enobosarm and sabizabulin. The company also has a Sexual Health Division with a PDUFA date for ENTADFI in December 2021. The release contains forward-looking statements regarding the efficacy and approval of its drug candidates.
Veru Inc. announced its inclusion in Deloitte’s Technology Fast 500™, recognizing significant growth in its revenue, which surged 212% from 2017 to 2020, primarily from its Sexual Health Division. The company focuses on oncology, particularly treatments for breast and prostate cancer. Key products include enobosarm and sabizabulin, with ongoing clinical studies for metastatic cancers and COVID-19 treatment. CEO Mitchell Steiner highlighted telemedicine as a growth driver, enabling further investment in their oncology pipeline.
Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical firm, announced participation in the Jefferies London Healthcare Conference from November 16-18, 2021. The fireside chat is set for November 18, available on-demand starting at 8:00 am GMT. The discussion will focus on their innovative cancer treatments, particularly for breast and prostate cancers, highlighting their ongoing clinical trials for enobosarm and sabizabulin. For access to the webcast, visit verupharma.com.
Veru Inc. (NASDAQ: VERU) has initiated the Phase 3 ARTEST trial, enrolling its first patient for enobosarm, a targeted hormone therapy for AR+ER+HER2- metastatic breast cancer. This trial, conducted across 49 sites in the U.S. and Europe, aims to evaluate the efficacy and safety of enobosarm versus active controls for patients previously treated with estrogen blockers and CDK4/6 inhibitors. A companion diagnostic test will be developed to identify the most suitable candidates. The study targets around 210 patients and aims to address a significant unmet need in breast cancer treatment.
Veru Inc. (NASDAQ: VERU) announced positive updated clinical data for sabizabulin (VERU-111) from a Phase 1b/2 study involving 80 men with metastatic castration-resistant prostate cancer. Presented at the ESMO Congress 2021, the findings indicate a median radiographic progression-free survival of approximately 7.4 months. Sabizabulin demonstrated a favorable safety profile, with no serious adverse events reported. These results support ongoing Phase 3 VERACITY study, aiming to confirm the drug's efficacy and safety as a treatment option for patients who have failed prior therapies.